SP142 evaluation contributes to the prediction of immune checkpoint inhibitor efficacy in non-small cell lung cancer with high PD-L1 expression assessed by 22C3

BACKGROUND: It remains unclear whether assessing programmed death-ligand 1 (PD-L1) expression by SP142 plus 22C3 adds value for predicting the response to immunotherapy in non-small cell lung cancer (NSCLC). METHODS: This retrospective multicenter study included patients with advanced NSCLC treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakahama, Kenji, Osawa, Masahiko, Izumi, Motohiro, Yoshimoto, Naoki, Sugimoto, Akira, Nagamine, Hiroaki, Ogawa, Koichi, Matsumoto, Yoshiya, Sawa, Kenji, Tani, Yoko, Kaneda, Hiroyasu, Mitsuoka, Shigeki, Watanabe, Tetsuya, Asai, Kazuhisa, Kawaguchi, Tomoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830255/
https://www.ncbi.nlm.nih.gov/pubmed/36636414
http://dx.doi.org/10.21037/tlcr-22-496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830255/
https://www.ncbi.nlm.nih.gov/pubmed/36636414
http://dx.doi.org/10.21037/tlcr-22-496

Ejemplares similares